The_DT
DNA_NN
and_CC
steroid_NN
binding_NN
domains_NNS
of_IN
the_DT
glucocorticoid_NN
receptor_NN
are_VBP
not_RB
altered_VBN
in_IN
mononuclear_JJ
cells_NNS
of_IN
treated_VBN
CLL_NN
patients_NNS
._.

The_DT
aim_NN
of_IN
this_DT
study_NN
was_VBD
to_TO
investigate_VB
whether_IN
mutations_NNS
in_IN
the_DT
glucocorticoid_NN
receptor_NN
could_MD
account_VB
for_IN
the_DT
increasing_VBG
unresponsiveness_NN
of_IN
patients_NNS
with_IN
chronic_JJ
lymphatic_JJ
leukemia_NN
-LRB-_-LRB-
CLL_NN
-RRB-_-RRB-
to_TO
combination_NN
chemotherapy_NN
._.

The_DT
receptor_NN
was_VBD
tested_VBN
immunocytochemically_RB
,_,
in_IN
steroid_NN
binding_NN
assays_NNS
,_,
and_CC
by_IN
a_DT
mutation_NN
screening_NN
-LRB-_-LRB-
denaturing_VBG
gradient_NN
gel_NN
electrophoresis_NN
-RRB-_-RRB-
of_IN
the_DT
receptor-cDNA_NN
._.

The_DT
receptor_NN
concentration_NN
,_,
as_IN
measured_VBN
by_IN
staining_NN
and_CC
steroid_NN
binding_NN
test_NN
,_,
varied_VBD
considerably_RB
but_CC
showed_VBD
no_DT
clear_JJ
correlation_NN
to_TO
clinical_JJ
response_NN
._.

Using_VBG
a_DT
highly_RB
sensitive_JJ
mutation_NN
screening_NN
assay_NN
of_IN
the_DT
DNA_NN
-_:
and_CC
the_DT
steroid-binding_JJ
region_NN
,_,
none_NN
of_IN
the_DT
treated_VBN
patients_NNS
revealed_VBD
any_DT
mutation_NN
,_,
suggesting_VBG
that_IN
the_DT
glucocorticoid_NN
receptor_NN
in_IN
the_DT
CLL_NN
patients_NNS
tested_VBN
is_VBZ
not_RB
altered_VBN
in_IN
these_DT
domains_NNS
._.

In_IN
one_CD
individual_JJ
who_WP
had_VBD
not_RB
been_VBN
treated_VBN
before_IN
analysis_NN
a_DT
silent_JJ
mutation_NN
was_VBD
found_VBN
in_IN
one_CD
receptor_NN
allele_NN
._.

The_DT
results_NNS
suggest_VBP
that_IN
mechanisms_NNS
other_JJ
than_IN
altered_JJ
ligand_NN
or_CC
DNA_NN
binding_NN
of_IN
the_DT
receptor_NN
may_MD
be_VB
responsible_JJ
for_IN
the_DT
lack_NN
of_IN
response_NN
to_TO
chemotherapy_NN
._.

This_DT
conclusion_NN
is_VBZ
discussed_VBN
in_IN
relation_NN
to_TO
the_DT
mechanism_NN
of_IN
corticoid_NN
resistance_NN
in_IN
mouse_NN
and_CC
human_JJ
lymphoma_NN
cells_NNS
in_IN
culture_NN
._.

